NCT04241835
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04241835
Title A Study of Oral Tazemetostat in Subjects With Moderate and Severe Hepatic Impairment With Advanced Malignancies
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Epizyme, Inc.
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | SVK | POL | FRA | BEL

Facility Status City State Zip Country Details
Florida Cancer Specialists & Research Institute Lake Mary Florida 32746 United States Details
Robert H. Lurie Comprehensive Cancer Center of Northwestern University Chicago Illinois 60611 United States Details
Hematology Oncology Consultants Royal Oak Michigan 48073 United States Details
Comprehensive Cancer Center of Nevada Las Vegas Nevada 89014 United States Details
Rutgers Cancer Institute New Brunswick New Jersey 08901 United States Details
Gabrail Cancer Center Canton Ohio 44718 United States Details
Mary Crowley Cancer Research Dallas Texas 75230 United States Details
Virginia Cancer Specialists Fairfax Virginia 22031 United States Details
Antwerp University Hospital Edegem Antwerp 2650 Belgium Details
Institut Bergonie Bordeaux 33076 France Details
Centre Oscar Lambret Lille 59020 France Details
Institut de Cancérologie Strasbourg Europe Strasbourg France Details
MedPolonia Poznan Greater Poland Voivodeship 60693 Poland Details
Summit Clinical Research, s.r.o Bratislava 831 01 Slovakia Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field